A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG).
Radiolabelled meta-iodobenzylguanidine (MIBG) is widely used in the diagnosis, follow-up and treatment of patients with tumours of neural crest origin. Some commonly prescribed and readily available over-the-counter medicines interfere with the uptake and biodistribution of this radiopharmaceutical. This may lead to poor concentration of radiolabelled MIBG within the target organs and tissues. The clinical implications are a potentially inaccurate assessment of tumour burden during diagnostic studies and a suboptimal radiation dose when MIBG is employed for targetted radiotherapy. In order to avoid false negative results a comprehensive list of prescribed and over-the-counter medicines that have the potential to inhibit uptake of MIBG has been compiled. It is hoped that this will help nuclear medicine physicians to avoid this pitfall.
Solanki
K K
KK
Department of Nuclear Medicine, St Bartholomew's Hospital, London, UK.
Bomanji
J
J
Moyes
J
J
Mather
S J
SJ
Trainer
P J
PJ
Britton
K E
KE
D019797:3-Iodobenzylguanidine; D004347:Drug Interactions; D006801:Humans; D007457:Iodine Radioisotopes; D007462:Iodobenzenes / Q000493:pharmacokinetics*; D004366:Nonprescription Drugs
D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D004366:Nonprescription Drugs; D019797:3-Iodobenzylguanidine